Faeth Therapeutics Announces Positive Phase 2 Topline Data for PIKTOR in Endometrial CancerFaeth Therapeutics reported preliminary Phase 2 clinical results evaluating PIKTOR in advanced endometrioid endometrial cancer.
Definium Therapeutics Announces Positive Phase 3 Topline Results for DT120 ODT in Generalized Anxiety DisorderPublished: 2026-11-11 05:55 EST Definium Therapeutics announced finalized topline results from two pivotal Phase 3 clinical trials on November 10, 2026.
Definium Therapeutics Announces DT120 ODT Meets Primary Endpoints in Two Phase 3 GAD TrialsClinical-stage biopharmaceutical developer Definium Therapeutics announced positive topline results from two pivotal Phase 3 trials evaluating DT120 orally disintegrating tablets.
UT Southwestern Study Shows Physician and Clinic Factors Outweigh Patient Demographics in Cancer Trial EnrollmentNational Dataset Challenges Long-Standing Assumptions The multi-center cohort investigation conducted by UT Southwestern researchers delivered transformative insights across oncology research…
Black Diamond Announces Positive Silevertinib Phase 2 NSCLC Brain Metastases Data with 86% CNS ResponsePrecision oncology biopharmaceutical developer Black Diamond Therapeutics reported positive updated Phase 2 clinical results on Tuesday for its investigational drug silevertinib.
Atea Pharmaceuticals Announces Phase 3 C-BEYOND Trial Met Primary Endpoint for Bemcentinib Regimen in Hepatitis CClinical-stage biopharmaceutical developer Atea Pharmaceuticals announced on Tuesday that its pivotal Phase 3 C-BEYOND trial met all primary efficacy endpoints in chronic hepatitis C.
Waters Corporation Obtains FDA 510(k) Clearance for CellStream Flow Cytometry Diagnostic Kit for LymphomaWaters Corporation (NYSE: WAT) announced on November 10, 2026, that it has received 510(k) premarket clearance from the U.S. Food and Drug Administration (FDA).
US FDA Grants De Novo Authorization for Virtuoso Endoluminal Robotic System for En Bloc Bladder Tumor ResectionThe United States Food and Drug Administration (FDA) granted De Novo classification authorization to Virtuoso Surgical Inc. on November 10, 2026, for its innovative Virtuoso Robotic System.
VeonGen Aligns With FDA on Pivotal Phase 3 Clinical Trial Design for Dual-AAV Gene Therapy VG801Clinical-stage ophthalmology biotechnology enterprise VeonGen announced on November 9, 2026, that it has reached formal regulatory alignment with the U.S.
Valneva Announces Positive Phase 2 Clinical Trial Results for Tetravalent Shigella Vaccine Candidate S4V2Specialty vaccine developer Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced successful Phase 2 clinical trial results on November 9, 2026, for its investigational tetravalent bioconjugate…
Trump Administration Announces $10 Billion in Rural Health Transformation Grants to All 50 StatesThe U.S. Department of Health and Human Services and the Centers for Medicare & Medicaid Services announced on November 9, 2026, the allocation of $10 billion in second-year funding awards under the…
Rubrik Introduces DevOps Protection with Cyber Recovery for Microsoft Azure DevOps and GitHub to Shield CI/CD PipelinesEnterprise cybersecurity and data resilience company Rubrik (NYSE: RBRK) officially announced the release of its DevOps Protection Enterprise Edition on Tuesday, November 10, 2026, delivering…
RESTEM Secures United States FDA Investigational New Drug Clearance for Phase 1/2 Clinical Trial of Restem-X in Knee OsteoarthritisClinical-stage biotechnology developer RESTEM officially announced on November 10, 2026, that the United States Food and Drug Administration (FDA) cleared its Investigational New Drug (IND)…
Merck Publishes Phase 2b Efinopegdutide Results in The Lancet Achieving 63% MASH Resolution at 52 WeeksMerck & Co., Inc. (NYSE: MRK) announced on Tuesday, November 10, 2026, that comprehensive results from its Phase 2b clinical trial evaluating investigational efinopegdutide (MK-6024) have been…
ImmunityBio Announces Positive Topline Results as ANKTIVA Plus BCG Meets Primary Endpoint in Phase 3 Bladder Cancer TrialCommercial immunotherapy leader ImmunityBio, Inc. (NASDAQ: IBRX) announced on November 9, 2026 that its pivotal randomized Phase 3 clinical trial met its primary efficacy endpoint.
Google Cloud Unveils Gemini for Healthcare Foundation Model Platform for Multimodal Clinical DiagnosticsGoogle Cloud launched its dedicated clinical AI solution, Gemini for Healthcare, on November 10, 2026. The launch took place at a technical keynote at its headquarters in Sunnyvale, California.
Federal Trade Commission and Five State Attorneys General File Federal Lawsuit Against Telehealth Provider Hims & HersThe Federal Trade Commission alongside attorneys general representing five sovereign states officially filed a sweeping federal complaint on Tuesday, November 10, 2026, against consumer telehealth…
FTC and Five State Attorneys General File Amended Complaint in Telehealth Privacy Lawsuit Against Hims & HersThe Federal Trade Commission (FTC) filed an amended civil complaint in federal district court on November 10, 2026, officially joining attorneys general from five states as co-plaintiffs in its…
US FDA Mandates Eye Stroke Warning for Ozempic, Wegovy, and Other GLP-1 Weight Loss MedicationsThe United States Food and Drug Administration on Monday ordered manufacturers of glucagon-like peptide-1 receptor agonists to update prescription prescribing information with warnings regarding…
FDA Mandates Class-Wide Safety Labeling Warnings for GLP-1 Receptor Agonists Over Vision Loss RiskThe United States Food and Drug Administration issued a formal Drug Safety Communication on Monday, November 9, 2026.
FDA Requires Safety Labeling Changes for All GLP-1 Receptor Agonists Due to NAION Vision Loss RiskThe U.S. Food and Drug Administration issued a comprehensive Drug Safety Communication on November 9, 2026, warning healthcare professionals and patients about a potential increased risk of…
FDA Mandates Class-Wide Safety Labeling Update for GLP-1 Drugs Warning of Potential Vision Loss from NAIONWASHINGTON - The United States Food and Drug Administration issued a comprehensive drug safety communication on Monday, November 9, requiring manufacturers of all approved glucagon-like peptide-1…
FDA Grants 510(k) Clearance for Cepheid Rapid Molecular Test Panel Identifying Ebola and Marburg VirusesThe United States Food and Drug Administration (FDA) approved a crucial molecular diagnostic tool on November 9, 2026, granting 510(k) clearance to medical technology pioneer Cepheid for its…
United States FDA Grants Marketing Clearance for Theraclion's Sonovein Focused Ultrasound System for Non-Invasive Varicose Vein AblationThe United States Food and Drug Administration (FDA) officially granted commercial marketing clearance on November 10, 2026, for the Sonovein focused ultrasound (FUS) robotic therapy system developed…
FDA Approves First-in-Class Oral CSF-1R Inhibitor Pimicotinib for Symptomatic Tenosynovial Giant Cell TumorThe U.S. Food and Drug Administration officially granted market approval for pimicotinib on Tuesday, November 10, 2026, marking a significant therapeutic breakthrough in rare oncology.
FDA Approves Promega OncoMate MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA in MSI-High Solid TumorsThe United States Food and Drug Administration officially approved the OncoMate MSI Dx Analysis System on Tuesday, November 10, 2026, clearing the molecular diagnostic assay developed by Promega…
United States FDA Approves Bayer's Novel Factor XIa Inhibitor Sunharbo to Prevent Recurrent Secondary Ischemic StrokeThe United States Food and Drug Administration (FDA) officially approved Bayer AG's first-in-class small-molecule anticoagulant Sunharbo (asundexian) on November 10, 2026, authorizing a 50 mg…
European Commission Approves Expanded Third-Line Indication for Oncopeptides' Pepaxti in Multiple MyelomaThe European Commission formally issued regulatory approval for a Type II variation application expanding the marketing authorization for Pepaxti (melphalan flufenamide, also known as melflufen) on…
Eli Lilly Reports Foundayo Oral GLP-1 Phase 3 Trial Significantly Reduced Obstructive Sleep Apnea SeverityGlobal pharmaceutical innovator Eli Lilly and Company announced positive top-line results from a pivotal Phase 3 clinical trial on November 9, 2026, evaluating its investigational oral once-daily…
Delaware Secures $160.3 Million Federal Grant to Expand Rural Healthcare Infrastructure in Southern CountiesNEW CASTLE, Del. - The Delaware Department of Health and Social Services announced on Monday, November 9, that the state has secured $160,294,521 in Year 2 federal funding under the federal Rural…
Compass Pathways Completes New Drug Application Submission to US FDA for COMP360 Psilocybin in DepressionLONDON - Mental healthcare biotechnology leader Compass Pathways plc announced on Monday, November 9, that it has completed its comprehensive New Drug Application (NDA) submission to the United…
FDA Accepts Supplemental New Drug Application for Celcuity's Revtorpyk in Advanced PIK3CA-Mutant Breast CancerMINNEAPOLIS - Clinical-stage biotechnology company Celcuity Inc. announced on Monday, November 9, that the United States Food and Drug Administration has formally accepted its supplemental New Drug…
Beam Therapeutics Reports Landmark Clinical Data from Pivotal BEACON Base Editing Sickle Cell Disease TrialPrecision genetic medicine pioneer Beam Therapeutics Inc. officially published positive topline clinical results from its pivotal BEACON trial on Tuesday, November 10, 2026.
FDA Grants Dual RMAT and Fast Track Designations to AbelZeta Bispecific CAR-T Prizlon-Cel for Large B-Cell LymphomaPrecision biopharmaceutical developer AbelZeta Pharma, Inc. announced on Tuesday, November 10, 2026, that the United States Food and Drug Administration granted dual regulatory milestones for its…
Abbott Receives FDA Approval and CE Mark for UltiSynq Defibrillation Lead Enabling Left Bundle Branch PacingAbbott (NYSE: ABT) announced on November 10, 2026, that it has received dual regulatory approvals from the U.S.
Viridian Therapeutics Announces Phase 1 Trial Data for VRDN-008 Showing 74 Percent Peak IgG Reduction Supporting Q8W DosingWALTHAM, Mass. - Viridian Therapeutics, Inc. filed a current report on Form 8-K with the Securities and Exchange Commission on Monday, November 9.
Vir Biotechnology Reports Phase 3 ECLIPSE 1 Data Showing 79% Viral Undetectability in Hepatitis DeltaSAN FRANCISCO - Biopharmaceutical developer Vir Biotechnology Inc. announced positive topline results from its pivotal Phase 3 ECLIPSE 1 clinical trial on Monday, November 9, demonstrating that 79…
American Heart Association Issues Updated 2026 Guidelines for Adult Stroke Rehabilitation and CareThe American Heart Association alongside the American Stroke Association published the 2026 Guideline for Adult Stroke Rehabilitation and Recovery on Sunday during a clinical plenary session in…
CDC Mpox Surveillance Report Confirms Unvaccinated Face Nearly Ten-Fold Higher Hospitalization Risk Amid Endemic ShiftThe United States Centers for Disease Control and Prevention (CDC) released comprehensive clinical surveillance findings in the Morbidity and Mortality Weekly Report (MMWR), revealing that…
FDA Expands Nationwide Public Health Alert on Lead-Tainted Ground Cinnamon to 21 BrandsSILVER SPRING, Md. — The U.S. Food and Drug Administration has expanded its nationwide public health alert regarding lead-contaminated ground cinnamon, adding a new product that brings the total…
Eli Lilly Advances Triple Hormone Agonist Retatrutide Across Global Phase 3 Obesity Clinical TrialsINDIANAPOLIS — Eli Lilly and Company published late-stage clinical data evaluating its investigational triple-hormone agonist retatrutide, confirming average weight loss of up to 30.3 percent among…
Boehringer Ingelheim Announces Survodutide Met Cardiovascular Safety Endpoints in Landmark Phase 3 SYNCHRONIZE-CVOT TrialCHICAGO - Boehringer Ingelheim and development partner Zealand Pharma announced positive top-line results on Monday, November 9, from the landmark Phase 3 SYNCHRONIZE-CVOT clinical trial presented at…
Vertex Phase 3 RAINIER Trial Data Demonstrates 49.8 Percent Proteinuria Reduction in IgA NephropathyBiotechnology leader Vertex Pharmaceuticals published complete clinical results from its pivotal Phase 3 RAINIER trial in the New England Journal of Medicine on Thursday.
FDA Grants Priority Review for uniQure's AMT-130 Gene Therapy in Huntington's DiseaseBiopharmaceutical developer uniQure N.V. submitted a Form 8-K filing to the U.S. Securities and Exchange Commission confirming that the Food and Drug Administration accepted its Biologics License…
AHA 2026 STREAM Trial Results Show Statin Deprescribing in Elderly Adults Meets Statistical NoninferiorityCardiovascular clinical researchers unveiled pivotal late-breaking clinical trial results on Sunday at the American Heart Association Scientific Sessions 2026 in Chicago.
American Heart Association Study Links Variable Sleep Schedules to 24% Higher Risk of Major Cardiovascular EventsPreliminary clinical research presented Sunday at the American Heart Association's Scientific Sessions 2026 in Chicago reveals that day-to-day inconsistencies in sleep timing and nightly duration…
Novo Nordisk Phase 3 ZEUS Trial Misses Primary Endpoint for Cardiovascular Risk ReductionNovo Nordisk reported top-line findings from the phase 3 ZEUS clinical trial on Sunday during the American Heart Association Scientific Sessions in Chicago.
Johnson & Johnson Reports Positive Phase 3 ICONIC-PsA 1 Trial Data for Oral Peptide ICOTYDE in Active Psoriatic ArthritisClinical Protocol Metrics and Endpoint Outcomes from the ICONIC-PsA 1 Trial Enrolled Patient Cohort & Stratification: 552 Biologic-Naive Adults with Active PsA Week 16 Primary Efficacy Endpoint…
Johnson & Johnson Reports Positive Phase 2 Nipocalimab Data Demonstrating Saliva Production Gains in Sjögren's DiseaseJohnson & Johnson released clinical outcome findings from its Phase 2 DAHLIAS trial evaluating investigational FcRn blocker nipocalimab in adults living with moderate-to-severe Sjögren's disease.
CDC Reports U.S. Teen HPV Vaccination Stalled for Fourth Straight Year as Experts Urge School-Based MandatesHuman papillomavirus (HPV) vaccination coverage among U.S. adolescents remained largely unchanged for a fourth consecutive year in 2025, according to surveillance findings published by the Centers…